



PAS



Normal EM


Bowman's space



Podocyte
foot process


LD

Capillary lumen




- | A 24 yr old man had been taking indomethacin for back pain. He noted sudden edema. BP was 140/96, urinalysis 3+ proteinuria, creatinine 80 $\mu\text{mol/L}$. What is the likely diagnosis?
 - u Minimal Change Nephropathy
 - u Interstitial nephritis
 - u Membranous GN
 - u SLE
 - u Diabetes

Normal glomerulus



Minimal change nephropathy



Minimal change



- | Nephrotic syndrome , mostly children
- | T-cell disorder
- | some FGS are misdiagnosed
 - u ? TGFB1 gene expression useful here
- | causes
 - u NSAIDs, rifampicin, ampicillin, interferon
 - u Hodgkins
 - u gold, lithium, tiopronin (rare)

Treatment of adult MCN


- | Steroids 2-4 months or until 1 week post remission, then taper 1-2 months
 - u 90% response
- | 30-50% relapse within 1 year
- | frequent relapsers or steroid dependence
 - u cyclophosphamide
 - u Cyclosporin

- | A 40 yr old man develops edema. Urinalysis shows 3+ protein and urine protein is 3.1g/day. Serum albumin is 30 and creatinine 90 $\mu\text{mol/L}$. Renal biopsy shows membranous GN. Which of the following is correct?
 - u He is likely to have renal vein thrombosis
 - u He should receive steroids alone
 - u He should receive ACEI but no immunosuppression unless his condition worsens
 - u He has a 25% risk of underlying Cancer
 - u He has a 25% risk of underlying SLE

Membranous GN



Membranous GN



Membranous GN

I Causes

- u malignancy

- u drugs

- u SLE / RA / other CTs

- u Hep B / C


- u schistosomiasis

- u syphilis

- u Sarcoid

- I podocyte-expressed M-type secretory phospholipase A2 receptor (PLA2R) is the target of autoantibodies in MGN

Natural history of membranous GN



Membranous GN

- | **Highest risk**
 - u males > 50 yrs
 - u proteinuria > 10g/d
 - u raised creatinine at presentation
- | **Best prognosis**
 - u women, young adults
 - u non-nephrotic
 - u drug induced


Treatment of membranous GN

- | **Non- nephrotic normal GFR**
 - u observe 6 months for remission or progression
- | **High risk for progression or thrombi**
 - u steroids alone inadequate
 - u chlorambucil / steroids for 6 months
 - u cyclophosphamide / steroids 6 months
- | other options
 - u Cyclosporin / NSAIDs / ACEI

| A 20 yr old woman went swimming in a public pool in Fiji. She returned to Australia almost 3 weeks later feeling generally unwell with numerous impetigo-like skin lesions. Soon after she developed oliguria. Creatinine rose to 1000 $\mu\text{mol/L}$ and urine showed rbc casts and 2+ proteinuria. The most likely diagnosis is:

- u Post streptococcal GN
- u SLE
- u Leptospirosis
- u Adult Henoch Schonlein purpura
- u Dengue fever

Post - infectious GN



Subepithelial 'hump' in PSGN



PSGN

- | Almost all recover completely
 - u hematuria lasts 3-6 months
 - u proteinuria in 15% at 3 yrs
 - u 1% ESRF
- | steroids not of benefit
- | some develop late (10 - 40 yrs)
 - u proteinuria
 - u hypertension
 - u renal insufficiency

MCGN

I Type 1

- u mesangial & subendothelial deposits

I Type 2

- u dense deposits BM, tubule membrane

I Type 3

- u subepithelial deposits predominant

- u large lucent areas in BM

Mesangiocapillary GN


| Type 1

- u SLE / Sjogren's
- u Hep B / C
- u mixed cryoglobulinemia
- u IE / schistosomiasis / shunt nephritis
- u chronic visceral abscess
- u CLL / NHL / leukemias
- u α 1 antitrypsin deficiency


| Type 2

- u dense deposit disease
- u C3 NeF / partial lipodystrophy


| Type 3



MCGN Type 1




MCGN Type 1



MCGN Type 1

Cellular proliferation



Double contours



Mesangiocapillary GN



| Outcome

- u 10% spontaneous improvement
- u 30% unchanged
- u 60% ESKD 10-15 yrs



| Treatments

- u steroids – uncontrolled data
 - u +/- aspirin, dipyridamole
- | no treatment of proven benefit


Crescentic Glomerulonephritis + fibrinoid necrosis



Anti - GBM disease




Crescentic GN



cellular

fibrosis



Crescentic GN

- | **Type 1** (10%) - antiGBM Ab
 - u Goodpasture's
- | **Type 2** (45%) - immune complex
 - u IgA / membranous / PIGN
 - u HSP
 - u SLE
 - u cryoglobulinemia
 - u IE
- | **Type 3** (45%) - pauci-immune (ANCA)
- | Type 4 : features of Type 1 and 3

Treatment of Crescentic GN

| Type 1

- u plasma exchange
- u steroids / cyclophosphamide
- u select if
 - u pulmonary haemorrhage
 - u creatinine < 600 $\mu\text{mol/L}$
- u remainder worse with therapy

Treatment of Crescentic GN

I **Types 2 / 3**

- u Plasma exchange if dialysis dependent or lung haemorrhage
- u steroids / cyclophosphamide
- u benefits may occur even if dialysis dependent eg. Wegner's

QUESTION 29

A week after a flu like illness, a 22-year-old presents with a haemorrhagic rash on the lower extremities (as shown in the figure below), and generalised arthralgia. The serum creatinine is elevated ($125 \mu\text{mol/L}$, [$<110 \mu\text{mol/L}$]) and there is blood and protein in the urine.



The most likely finding on renal biopsy is:

- A. glomerular microangiopathy (haemolytic-uraemic syndrome).
- B. mesangiocapillary glomerulonephritis.
- C. Henoch-Schönlein nephropathy.
- D. antineutrophil cytoplasmic antibody (ANCA) positive vasculitis.
- E. lupus nephropathy.

IgA nephropathy



I Causes

- u cirrhosis
- u coeliac disease
- u dermatitis herpetiformis
- u seronegative arthritis
- u HSP
- u HIV
- u mycosis fungoides


I Course

- u 15% CRF 10 yrs
- u 20% CRF 20 yrs
- u further 20% renal insufficiency at 20 yrs
- u **possibly underestimates**

IgA nephropathy



IgA nephropathy



IgA nephropathy



IgA nephropathy

I Predictors of progression

- u impaired GFR at presentation
- u proteinuria > 1g / d
- u hypertension

- u glomerulosclerosis
- u interstitial fibrosis
- u crescents

IgA nephropathy

- | **Treatments** (all unproven)
 - u steroids
 - u cyclophosphamide
 - u fish oil
 - u CyA
 - u ivi immune globulin
 - u ACEI

Trials of patients with proteinuric IgAN

Table 1 | Comparison of recent trials of patients with proteinuric IgAN^{1,2}

Parameter	Manno <i>et al.</i> ¹		Lv <i>et al.</i> ²	
	ACEI arm	Combination* arm	ACEI arm	Combination* arm
Number of participants	46	45	29	31
Mean baseline eGFR (ml/min/1.73m ²) [‡]	98	100	102	101
Mean baseline proteinuria (g per day) [‡]	1.5	1.7	2.0	2.5
ACEI	Ramipril	Ramipril	Cilazapril	Cilazapril
Maximum daily ACEI dose (mg)	6.7	6.5	Unavailable (initial 2.5; target 5.0)	Unavailable (initial 2.5; target 5.0)
Prednisone treatment	NA	6 months; 1.0mg/kg per day for 2 months and then taper by 0.2 mg/kg per day every month	NA	6–8 months; 0.8–1.0mg/kg per day for 8 weeks, then taper by 5–10 mg every 2 weeks
Mean follow-up (months)	57	63	28	26
Mean blood pressure at end of follow-up (mmHg)	121/77	121/77	Unavailable	Unavailable
Patients reaching the study's primary outcome	27% [§]	4% [§]	24%	3%

*Therapy including administration of an ACEI and prednisone. [‡]In the absence of ACEI therapy. [§]Doubling of baseline serum creatinine from baseline or end-stage renal disease. ^{||}50% increase in serum creatinine level from baseline. Abbreviations: ACEI, angiotensin-converting-enzyme inhibitor; eGFR, estimated glomerular filtration rate; NA, not applicable.

Recommendation:



Maximise
ACEI/ARB & BP
control first;

If proteinuria still >
1g/d trial 6 months
PRD .

Frank Eitner and Jürgen Floege (2010) ACEIs with or without corticosteroids in IgA nephropathy?
Nat. Rev. Nephrol. doi:10.1038/nrneph.2010.31

- | A 50 yr old man presents with hypertension (170/100) and proteinuria 3g/day. Creatinine is 100umol/L. Renal biopsy shows FSGS. Which of the following are correct:
 - u Rituximab is now considered the best treatment for this disorder
 - u This may be secondary to poorly controlled hypertension
 - u Most adults with FSGS will need dialysis within 5 years
 - u HIV does not induce this lesion
 - u This disorder is more common in children than adults

Focal Glomerulosclerosis



FGS - causes

I Primary

- u idiopathic
- u familial - autosomal dominant, Chr 19
 - u gain of function mutation α -actinin 4
 - u linked to increase podocyte cytoskeleton
- u HIV
- u lithium (chronic toxicity)
- u Hodgkin's & NHL
- u heroin

FGS - causes

I Secondary

- u healing of prior glomerular disease
 - u e.g.SLE, IgA, vasculitis
- u nephron loss
 - u reflux, hypertension, ischaemia, ?nephrectomy
- u glomerular hypertension
 - u diabetes, sickle cell, Type 1 GSD
- u obesity

Natural history of primary FGS

- | **Nephrotic**
 - u 40-70% ESRF at 10 yrs
- | **Non - nephrotic**
 - u 10-15% ESRF at 10yrs
- | **'responders'** to therapy
 - u 10% ESRF at 10 yrs
- | **'non - responders'** to therapy
 - u 60-80% ESRF at 10 yrs

Treatment of FGS

| Trial of steroids

- u up to 50% remission if treated 5-8 mths
- u all responders are within 9 months
- u steroid resistance likely if :
 - u tubulointerstitial disease
 - u secondary FGS
 - u elevated creatinine
 - u proteinuria > 10g/d

| CyA

- | tacrolimus + steroids if dependent on CyA
- | MMF used with success - no controlled trials
- | NSAIDs / ACEI

FSGS

- | Increasing frequency & new demographics
 - u Age 50-70, no longer 20-30
- | 10yr renal survival determined by response to treatment
 - u 90% if complete remission
 - u 80% if partial remission
 - u 40% if no remission
- | As pts now older, more obese, more co-morbidities
 - u Use CyA 1st (1mg/kg bd)
 - u No controlled data

Classification of Glomerulonephritis

| Diffuse

- u minimal change
- u membranous
- u proliferative
 - u PIGN / PSGN
 - u MCGN
 - u mesangial
 - u crescentic

| Focal

- u IgA
- u FGS
- u Thin basement membrane disease